Transparency in Action: FDA Comments on Pirfenidone
This article was originally published in RPM Report
Executive Summary
While FDA's proposed transparency initiative is still under discussion, there are signs that the agency is already taking a more liberal view of its disclosure polices. InterMune's pirfenidone is a case in point.
You may also be interested in...
FDA Releases Report on Transparency to Regulated Industry: Not Much To See Here
The third phase of the Food & Drug Administration’s Transparency Initiative lists 19 ways that the agency plans to improve transparency to the industries it regulates. FDA is also seeking comments on five proposed steps. Unlike earlier phases, there isn’t too much to see here.
Open Season at Open Sessions: Benlysta May Presage Resurgence of Public Pressure on FDA Committees
FDA would be wise to prepare for a new round of active, emotive open public sessions after the impact of the public testimony at the Benlysta lupus drug review on November 16. It’s been a long-time since a public session has had such a direct impact on creating a pro-approval atmosphere at a committee meeting.
FDA Opens Up: Can Industry Live With Greater Transparency?
Drug sponsors are finding little to like about FDA's transparency initiative-especially proposals that would allow the agency to disclose more about products still in development. But given the public interest in greater transparency-and FDA's interest in avoiding another Avandia-industry needs to decide whether this is a fight worth having.